New Horizon Health Limited (6606.HK)
New Horizon Health Limited
T1 Building
13th Floor 400 Jianger Road Binjiang District
Hangzhou 310052
China
86 57 1811 07210
https://ir.newhorizonbio.com
Sector(es): Healthcare
Industria: Medical Devices
Empleados a tiempo completo: 1,041
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Yeqing Zhu | CEO, Executive Chairman & Co-founder | 10.87M | N/D | 1972 |
| Dr. Yiyou Chen Ph.D. | Executive Director & Chief Scientific Officer | 5.59M | N/D | 1972 |
| Mr. Yu Gao | CFO & Joint Company Secretary | N/D | N/D | 1983 |
| Dr. Ning Lu | Chief Technology Officer | N/D | N/D | 1971 |
| Ms. Ming-Wai Mok | Joint Company Secretary | N/D | N/D | N/D |
Descripción
New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People's Republic of China. Its products include ColoClear, an early screening products for colon cancer; Pupu Tube, a fecal occult blood self test product; and UU Tube, a helicobacter pylori self-test products. The company is also involved in the research and development of medical diagnostic technology; provision of technical services, transfers, and consultation; and medical services, as well as financing services; manufacturing and sales of medical and laboratory equipment, and fecal occult blood test kits; and technological import and export activities. The company was founded in 2015 and is headquartered in Hangzhou, China.
Gestión corporativa
La calificación ISS Governance QuickScore de New Horizon Health Limited a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
